AR119270A1 - MÉTODOS PARA PRODUCIR UN ANTICUERPO ANTI-a4b7 - Google Patents
MÉTODOS PARA PRODUCIR UN ANTICUERPO ANTI-a4b7Info
- Publication number
- AR119270A1 AR119270A1 ARP200101641A ARP200101641A AR119270A1 AR 119270 A1 AR119270 A1 AR 119270A1 AR P200101641 A ARP200101641 A AR P200101641A AR P200101641 A ARP200101641 A AR P200101641A AR 119270 A1 AR119270 A1 AR 119270A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- methods
- vedolizumab
- produce
- integrin antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
En la presente se proporcionan métodos para purificar un anticuerpo anti-a4b7 integrina, tal como vedolizumab, a partir de una solución líquida, p. ej., a partir de una extracción aclarada de un cultivo celular de mamífero. La presente se relaciona, inter alia, con métodos de purificación para controlar la cantidad de sustancias relacionadas con el producto y/o impurezas relacionadas con el proceso que están presentes en preparaciones purificadas de un anticuerpo anti-a4b7 integrina, o en un fragmento de unión a antígeno de este, p. ej., vedolizumab. También se proporcionan composiciones que comprenden un anticuerpo anti-a4b7, y usos de este para tratar un trastorno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962859494P | 2019-06-10 | 2019-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119270A1 true AR119270A1 (es) | 2021-12-09 |
Family
ID=73781728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101641A AR119270A1 (es) | 2019-06-10 | 2020-06-10 | MÉTODOS PARA PRODUCIR UN ANTICUERPO ANTI-a4b7 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220267449A1 (es) |
| EP (1) | EP3980466A4 (es) |
| JP (2) | JP7624414B2 (es) |
| CN (2) | CN119859188A (es) |
| AR (1) | AR119270A1 (es) |
| AU (1) | AU2020290943A1 (es) |
| BR (1) | BR112021024897A2 (es) |
| CA (1) | CA3143167A1 (es) |
| IL (1) | IL288825A (es) |
| MA (1) | MA56129A (es) |
| MX (1) | MX2021015300A (es) |
| PL (1) | PL439809A1 (es) |
| TW (1) | TW202112818A (es) |
| WO (1) | WO2020252069A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12024561B2 (en) * | 2018-04-10 | 2024-07-02 | Dr. Reddy's Laboratories Limited | Stable antibody formulation |
| EP3773696A4 (en) | 2018-04-10 | 2021-12-29 | Dr. Reddy's Laboratories Ltd. | Stable formulations of therapeutic antibody |
| WO2023007516A1 (en) * | 2021-07-29 | 2023-02-02 | Dr. Reddy’S Laboratories Limited | Method to control high molecular weight aggregates in an antibody composition |
| EP4380948A4 (en) * | 2021-08-05 | 2025-07-16 | Dr Reddys Laboratories Ltd | METHOD FOR PURIFYING AN ANTIBODY COMPOSITION BY MEANS OF CATION EXCHANGE CHROMATOGRAPHY |
| WO2023031965A1 (en) * | 2021-09-03 | 2023-03-09 | Dr. Reddy’S Laboratories Limited | Method to obtain a purified antibody composition |
| WO2024233992A2 (en) * | 2023-05-11 | 2024-11-14 | Trophogen, Inc. | Methods of manufacturing highly glycosylated glycoprotein hormones and their analogs |
| AU2024282654A1 (en) | 2023-05-30 | 2025-12-04 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5429746A (en) * | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| WO2014142882A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Protein purification using displacement chromatography |
| DK3116891T3 (da) * | 2014-03-10 | 2020-05-04 | Richter Gedeon Nyrt | Immunglobulinrensning ved hjælp af forrensningstrin |
| MA41636A (fr) * | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
-
2020
- 2020-06-10 EP EP20822340.4A patent/EP3980466A4/en active Pending
- 2020-06-10 CN CN202510051206.5A patent/CN119859188A/zh active Pending
- 2020-06-10 MA MA056129A patent/MA56129A/fr unknown
- 2020-06-10 MX MX2021015300A patent/MX2021015300A/es unknown
- 2020-06-10 AR ARP200101641A patent/AR119270A1/es unknown
- 2020-06-10 WO PCT/US2020/037059 patent/WO2020252069A1/en not_active Ceased
- 2020-06-10 JP JP2021573298A patent/JP7624414B2/ja active Active
- 2020-06-10 US US17/596,421 patent/US20220267449A1/en active Pending
- 2020-06-10 PL PL439809A patent/PL439809A1/pl unknown
- 2020-06-10 CN CN202080049572.2A patent/CN114375307B/zh active Active
- 2020-06-10 CA CA3143167A patent/CA3143167A1/en active Pending
- 2020-06-10 TW TW109119563A patent/TW202112818A/zh unknown
- 2020-06-10 BR BR112021024897A patent/BR112021024897A2/pt unknown
- 2020-06-10 AU AU2020290943A patent/AU2020290943A1/en active Pending
-
2021
- 2021-12-09 IL IL288825A patent/IL288825A/en unknown
-
2024
- 2024-12-13 JP JP2024218770A patent/JP2025063035A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114375307A (zh) | 2022-04-19 |
| CN119859188A (zh) | 2025-04-22 |
| WO2020252069A1 (en) | 2020-12-17 |
| US20220267449A1 (en) | 2022-08-25 |
| AU2020290943A1 (en) | 2022-02-03 |
| JP2022536486A (ja) | 2022-08-17 |
| TW202112818A (zh) | 2021-04-01 |
| JP2025063035A (ja) | 2025-04-15 |
| JP7624414B2 (ja) | 2025-01-30 |
| EP3980466A1 (en) | 2022-04-13 |
| CA3143167A1 (en) | 2020-12-17 |
| MA56129A (fr) | 2022-04-13 |
| CN114375307B (zh) | 2025-12-05 |
| EP3980466A4 (en) | 2023-06-07 |
| IL288825A (en) | 2022-02-01 |
| MX2021015300A (es) | 2022-02-03 |
| BR112021024897A2 (pt) | 2022-01-18 |
| PL439809A1 (pl) | 2022-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119270A1 (es) | MÉTODOS PARA PRODUCIR UN ANTICUERPO ANTI-a4b7 | |
| AR124871A2 (es) | Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes | |
| AR120668A2 (es) | Métodos y composiciones para tolerancia a herbicidas en plantas | |
| ZA201804654B (en) | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates | |
| RU2010125605A (ru) | Антитело против глипикана-3 с улучшенными кинетическими показателями в плазме | |
| BR112015017307A2 (pt) | composições de espécies com baixa acidez e métodos para produção e uso das mesmas | |
| HRP20251020T1 (hr) | Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3 | |
| MY193112A (en) | Anti pd-1 and anti-lag3 antibodies for cancer treatment | |
| WO2015031654A3 (en) | Systems, compositions, and methods for transplantation and treating conditions | |
| MX2013003681A (es) | Ácidos nucleicos manipulados y métodos de uso de los mismos. | |
| MX2021000211A (es) | Metodos y productos para transfeccion de celulas. | |
| BR112015022770A8 (pt) | meio e sistema de cultivo da célula livre de xenógeno, livre de albumina, forma concentrada, métodos de diferenciação de células-tronco pluripotentes humanas, para a produção de mesenquimoangioblastos e sistema definido de cultivo da célula para diferenciação hematoendotelial das células- tronco pluripotentes humanas | |
| BR112012013875B8 (pt) | método in vitro para reprogramar células somáticas humanas ou de outros mamíferos para células tronco pluripotentes induzidas (células ips ou ipscs) e composição | |
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| MX2020003798A (es) | Metodos para la purificacion de arilsulfatasa a. | |
| AR085955A1 (es) | Proteinas de union al antigeno | |
| BR112021024848A2 (pt) | Métodos de purificação de anticorpos e composições dos mesmos | |
| AR095418A1 (es) | Métodos para aumentar el contenido de manosa en proteínas recombinantes | |
| EA202190736A1 (ru) | Способы и композиции для увеличения экспрессии белка и/или лечения расстройства, связанного с гаплонедостаточностью | |
| MX387420B (es) | Producción de virus en cultivos celulares. | |
| PE20190627A1 (es) | Preparacion farmaceutica antienvejecimiento | |
| AR077217A1 (es) | Medios para cultivo de celulas de mamiferos que comprenden sobrenadante de etapas del fraccionamiento de cohn y uso de los mismos | |
| PH12017502389A1 (en) | Jasmonic acid pathway activator | |
| BR112017016110A2 (pt) | composições de imunoglobulina equina e usos para tratamento de doenças mediadas por filovírus | |
| MX393714B (es) | Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo. |